Clinical Trial Update: Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update on long-term safety and tolerability of canakinumab prefilled syringes in patients with frequently flaring acute gouty arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gouty Arthritis

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Gouty Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2021-07-19